The “cancer immunogram”
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Visualizing the state of cancer–immune system interactions may spur personalized therapy
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“markers of response to cancer therapy have continued to evolve and now include factors well beyond established tumor-centric markers”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Blank et al., 2016
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Cited by
Items 301–400 of 748
Drug delivery methods for cancer immunotherapy
Pérez‐Herrero, E., Lanier, O. L., Krishnan, N., D’Andrea, A., & Peppas, N. A. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01405-9 · Cited by 33
Zhu, Y., Zhao, F., Li, Z., & Yu, J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s167400 · Cited by 29
Strategies for Predicting Response to Checkpoint Inhibitors
Zappasodi, R., Wolchok, J. D., & Merghoub, T. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0471-9 · Cited by 30
Léon-Letelier, R. A., Bonifaz, L. C., & Fuentes‐Pananá, E. M. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0618-241rr · Cited by 31
Himoto, Y., Veeraraghavan, H., Zheng, J., Zamarin, D., Snyder, A., Capanu, M., Nougaret, S., Vargas, H. A., Shitano, F., Callahan, M. K., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00038 · Cited by 30
Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
Ho, R. L. Y., & Ho, I. A. W. (2021) · Cancers · doi:10.3390/cancers13153686 · Cited by 34
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?
de Olza, M. O., Oliva, M., Hierro, C., Matos, I. G., Martín-Liberal, J., & Garralda, E. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy225 · Cited by 29
Gil-Jimenez, A., van Dijk, N., Vos, J. L., Lubeck, Y., van Montfoort, M. L., Peters, D. D. G. C., Hooijberg, E., Broeks, A., Zuur, C. L., van Rhijn, B. W. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46450-1 · Cited by 35
Zhang, N., Yang, M., Yang, J., Zhang, C., & Guo, A. (2024) · Small Methods · doi:10.1002/smtd.202301685 · Cited by 30
Chae, Y. K., Oh, M. S., & Giles, F. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0354 · Cited by 28
Zilenaite-Petrulaitiene, D., Rasmusson, A. G., Augulis, R., Besusparis, J., Laurinavičienė, A., Plancoulaine, B., Ostapenko, V., & Laurinavičius, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00950 · Cited by 28
Kim, S., Chun, S. H., Kim, J. R., Kim, S., Seo, J. Y., Jung, C. K., Gil, B. M., Kim, J.-O., Ko, Y. H., Woo, I. S., et al. (2021) · BMC Cancer · doi:10.1186/s12885-020-07727-y · Cited by 28
Neoantigen landscape in metastatic nasopharyngeal carcinoma
Lin, M. F., Zhang, X., You, R., Yang, Q., Zou, X., Yu, K., Liu, Y., Zou, R., Hua, Y., Huang, P., et al. (2021) · Theranostics · doi:10.7150/thno.53229 · Cited by 31
The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy
Lee, J. Y., Kannan, B., Lim, B. Y., Li, Z., Lim, A. H., Loh, J. W., Ko, T. K., Ng, C. C. Y., & Chan, J. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147839 · Cited by 31
Immunotherapy-based combinations: an update
Fucà, G., de Braud, F., & Nicola, M. D. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000466 · Cited by 27
Shields, N. J., Peyroux, E. M., Ferguson, A. L., Steain, M. C., Neumann, S., & Young, S. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152035 · Cited by 33
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
Versluis, J. M., Blankenstein, S. A., Dimitriadis, P., Wilmott, J. S., Elens, R., Blokx, W. A. M., van Houdt, W. J., Menzies, A. M., Schrage, Y. M., Wouters, M. W. J. M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008125 · Cited by 31
Bettariga, F., Taaffe, D. R., Borsati, A., Avancini, A., Pilotto, S., Lazzarini, S. G., López, P., Maestroni, L., Crainich, U., Campbell, J. P., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf062 · Cited by 36
Mair, M. J., Pajenda, S., Ilhan‐Mutlu, A., Steindl, A., Kiesel, B., Widhalm, G., Dieckmann, K. U., Feldmann, K., Hainfellner, J. A., Marosi, C., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000863 · Cited by 26
Microfluidic Tumor Vasculature Model to Recapitulate an Endothelial Immune Barrier Expressing FasL
Kim, S., Park, J., Kim, J., & Jeon, J. S. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01542 · Cited by 28
Creemers, J. H. A., Lesterhuis, W. J., Mehra, N., Gerritsen, W. R., Figdor, C. G., de Vries, I. J. M., & Textor, J. C. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002032 · Cited by 30
Gorris, M. A. J., van der Woude, L. L., Kroeze, L. I., Bol, K. F., Verrijp, K. N., Amir, A. L., Meek, J., Textor, J. C., Figdor, C. G., & de Vries, I. J. M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004329 · Cited by 35
Onesti, C. E., Josse, C., Poncin, A., Frères, P., Poulet, C., Bours, V., & Jérusalem, G. (2018) · Oncotarget · doi:10.18632/oncotarget.26120 · Cited by 30
Sato, Y., Nakamura, T., Yamada, Y., & Harashima, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.006 · Cited by 28
Fujino, S., Myoshi, N., Saso, K., Sasaki, M., Ishikawa, S., Takahashi, Y., Yasui, M., Ohue, M., Hata, T., Matsuda, C., et al. (2019) · Surgery Today · doi:10.1007/s00595-019-01861-2 · Cited by 30
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
Cuyàs, E., Verdura, S., Martín-Castillo, B., Alarcón, T., Lupu, R., Bosch‐Barrera, J., & Menéndez, J. A. (2020) · Cancers · doi:10.3390/cancers12071757 · Cited by 28
Immunotherapy in breast cancer: A clinician's perspective
Chaudhuri, S., Thomas, S., & Münster, P. N. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.01.001 · Cited by 26
Keukeleire, S. D., Vermassen, T., Hilgert, E., Creytens, D., Ferdinande, L., & Rottey, S. (2021) · Cancers · doi:10.3390/cancers13071714 · Cited by 26
The effects of acute exercise and inflammation on immune function in early-stage prostate cancer
Schauer, T., Djurhuus, S. S., Simonsen, C., Brasso, K., & Christensen, J. F. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100508 · Cited by 31
The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges
Solinas, C., Chanzá, N. M., Awada, A. H., & Scartozzi, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.004 · Cited by 26
Can Exercise Enhance the Efficacy of Checkpoint Inhibition by Modulating Anti-Tumor Immunity?
Brummer, C., Pukrop, T., Wiskemann, J., Bruß, C., Ugele, I., & Renner, K. (2023) · Cancers · doi:10.3390/cancers15184668 · Cited by 26
Buiting, H. M., van Ark, M. A. C., Dethmers, O., Maats, E. P. E., Stoker, J. A., & Sonke, G. S. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024450 · Cited by 25
The Adaptive and Innate Immune Cell Landscape of Uterine Leiomyosarcomas
Manzoni, M., Bolognesi, M. M., Antoranz, A., Mancari, R., Carinelli, S. G., Faretta, M., Bosisio, F. M., & Cattoretti, G. (2020) · Scientific Reports · doi:10.1038/s41598-020-57627-1 · Cited by 26
Rittberg, R., Harlos, C. H., Rothenmund, H., Das, A., Tabori, U. Y., Sinha, N., Singh, H., Chodirker, B. N., & Kim, C. (2021) · Current Oncology · doi:10.3390/curroncol28010074 · Cited by 25
Informing the new developments and future of cancer immunotherapy
Kumar, A., Swain, C. A., & Shevde, L. A. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09967-1 · Cited by 27
Mistry, K., Levell, N. J., Craig, P. J., Steven, N. M., & Venables, Z. C. (2021) · Skin Health and Disease · doi:10.1002/ski2.55 · Cited by 25
Kosari, F., Disselhorst, M., Yin, J., Peikert, T., Udell, J. B. M., Johnson, S. H., Smadbeck, J. B., Murphy, S. J., McCune, A., Karagouga, G., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.022 · Cited by 25
Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review
ter Maat, L. S., van Duin, I. A. J., Elias, S. G., van Diest, P. J., Pluim, J. P. W., Verhoeff, J. J. C., de Jong, P. A., Leiner, T., Veta, M., & Suijkerbuijk, K. P. M. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.034 · Cited by 21
Thiel, U., Schober, S. J., Einspieler, I., Kirschner, A., Thiede, M., Schirmer, D., Gall, K., Blaeschke, F., Schmidt, O., Jabar, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1312239 · Cited by 24
Vallonthaiel, A. G., Malik, P. S., Singh, V., Kumar, V., Kumar, S., Sharma, M. C., Mathur, S. R., Arava, S., Guleria, R., & Jain, D. (2017) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2017.07.001 · Cited by 24
The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?
Kerr, K. M. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.01.020 · Cited by 25
Criscitiello, C., Marra, A., Morganti, S., Zagami, P., Viale, G., Espósito, A., & Curigliano, G. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0518 · Cited by 26
Revolutionizing Pathology with Artificial Intelligence: Innovations in Immunohistochemistry
Poalelungi, D. G., Neagu, A., Fulga, A., Neagu, M., Tutunaru, D., Nechita, A., & Fulga, I. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070693 · Cited by 30
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
Fenton, S. E., Sosman, J. A., & Chandra, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.28 · Cited by 37
García‐Marín, R., Reda, S., Riobello, C., Cabal, V. N., Suárez–Fernández, L., Vivanco, B., López, F., Llorente, J. L., & Hermsen, M. A. J. A. (2020) · Vaccines · doi:10.3390/vaccines8020202 · Cited by 28
Funingana, I.-G., Reinius, M. A. V., Petrillo, A., Ang, J. E., & Brenton, J. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.008 · Cited by 23
Wu, J., & Lin, D. (2021) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000322 · Cited by 24
Conte, M., & Cauda, V. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200079 · Cited by 29
Gutierrez, E., Bigelow, M., LaCroix, C., Beech, J., Kirby, P. J., Markowitz, L., Shifrin, M., Naill, M., Braun, A., O'Neil, S., et al. (2023) · Med · doi:10.1016/j.medj.2023.03.007 · Cited by 25
Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma
Hoeijmakers, L. L., Reijers, I. L. M., & Blank, C. U. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0352 · Cited by 28
Informatics for cancer immunotherapy
Hammerbacher, J., & Snyder, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx682 · Cited by 24
de Heer, E. C., Brouwers, A. H., Boellaard, R., Sluiter, W. J., Diercks, G. F. H., Hospers, G. A. P., de Vries, E. G. E., & Jalving, M. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0453-x · Cited by 26
Rational combination of cancer immunotherapy in melanoma
Mandalà, M., & Rutkowski, P. L. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2506-y · Cited by 23
García-Marín, R., Reda, S., Riobello, C., Cabal, V. N., Suárez-Fernández, L., Vivanco, B., Álvarez-Marcos, C., López, F., Llorente, J., & Hermsen, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136926 · Cited by 16
Wu, J., Sun, W., Yang, X., Wang, H., Liu, X., Chi, K., Zhou, L., Huang, X., Mao, L., Zhao, S., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00903-w · Cited by 25
Han, W., Cheung, A., Yaffe, M. J., & Martel, A. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-08355-1 · Cited by 22
Han, R. F., Zhang, Y., Wang, T., Xiao, H., Luo, Z., Shen, C., Li, J., Zhao, C., Li, L., Zhu, M., et al. (2022) · Cancer Science · doi:10.1111/cas.15778 · Cited by 23
Savva, C., Copson, E., Johnson, P., Cutress, R., & Beers, S. A. (2023) · Cancers · doi:10.3390/cancers15092440 · Cited by 27
Mapping the functional interactions at the tumor-immune checkpoint interface
Bozorgui, B., Kong, E., Luna, A., & Korkut, A. (2023) · Communications Biology · doi:10.1038/s42003-023-04777-3 · Cited by 23
Chemotherapy for recurrent/metastatic head and neck cancers
Karabajakian, A., Toussaint, P., Neidhardt, E., Paulus, V., Saintigny, P., & Fayette, J. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000473 · Cited by 22
Distinct immune evasion in APOBEC ‐enriched, HPV ‐negative HNSCC
Messerschmidt, C., Obermayer, B., Klinghammer, K. F., Ochsenreither, S., Treue, D., Stenzinger, A., Glimm, H., Fröhling, S., Kindler, T., Brandts, C., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33123 · Cited by 22
Bakker, N. A. M., Garner, H., van Dyk, E., Champanhet, E., Klaver, C., Duijst, M., Voorwerk, L., Nederlof, I., Voorthuis, R. A. B., Liefaard, M. C., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00721-2 · Cited by 28
Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy
Song, Y., Li, Z., Xue, W., & Zhang, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0173 · Cited by 22
Prospective Artificial Intelligence to Dissect the Dengue Immune Response and Discover Therapeutics
Natali, E. N., Babrak, L. M., & Miho, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.574411 · Cited by 25
The immunogram of inflammatory breast cancer
Valenza, C., Trapani, D., Fusco, N., Wang, X., Cristofanilli, M., Ueno, N. T., & Curigliano, G. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102598 · Cited by 22
Biomarkers and experimental models for cancer immunology investigation
Xu, H., Jia, Z., Liu, F., Li, J., Huang, Y., Jiang, Y., Pu, P., Shang, T., Tang, P., Zhou, Y., et al. (2023) · MedComm · doi:10.1002/mco2.437 · Cited by 24
Terán-Navarro, H., Calderón-González, R., Salcines-Cuevas, D., García, I., Marradi, M., Freire, J., Salmon, E., Portillo-Gonzalez, M., Frande‐Cabanes, E., García‐Castaño, A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1541534 · Cited by 26
Lan, C., Lu, H., Zhou, L., Liao, K., Liu, J., Xie, Z., Liang, H., Zou, G., Yang, T., Xu, Q., et al. (2024) · 癌症:英文版 · doi:10.1002/cac2.12547 · Cited by 29
Bertolli, E., Franke, V., Calsavara, V. F., de Macêdo, M. P., Pinto, C. A. L., van Houdt, W. J., Wouters, M. W. J. M., Neto, J. P. D., & van Akkooi, A. C. J. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-7038-9 · Cited by 20
Zhang, X., Wang, S., Nie, R., Qu, C., Chen, J., Yang, Y., & Cai, M. (2022) · Cancers · doi:10.3390/cancers14030615 · Cited by 21
Multimodal predictors for precision immunotherapy
Roelofsen, L. M., Kaptein, P., & Thommen, D. S. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100071 · Cited by 19
Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas
Nesseler, J. P., Schaue, D., McBride, W. H., Lee, M.-H., Kaprealian, T. B., Niclou, S. P., & Nickers, P. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.11.005 · Cited by 21
The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma
Zhao, X., Little, P., Hoyle, A. P., Pegna, G. J., Hayward, M. C., Ivanova, A., Parker, J. S., Marron, D. L., Soloway, M. G., Jo, H., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00584 · Cited by 22
Liang, J., Liu, Z., Pei, T., Xiao, Y., Zhou, L., Tang, Y., Zhou, C., Wu, K., Zhang, F., Zhang, F., et al. (2020) · Disease Markers · doi:10.1155/2020/5354825 · Cited by 20
Melanoma immunotherapy: strategies to overcome pharmacological resistance
Trojaniello, C., Vitale, M. G., Scarpato, L., Esposito, A., & Ascierto, P. A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1745634 · Cited by 23
Güven, D. C., Şahin, T. K., Dızdar, Ö., & Kılıçkap, S. (2020) · Biomarkers in Medicine · doi:10.2217/bmm-2020-0310 · Cited by 20
Synthesis, molecular docking, ADMET profiling, and anti-PC3 activity of new Schiff base derivatives
Kamil, D. Q., Wasmi, A. H., Alhaidry, W. A. A. H., Al-Hussainawy, M. K., & Kyhoiesh, H. A. K. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101916 · Cited by 19
Immunotherapy in Head and Neck Squamous Cell Cancer
Denaro, N., & Merlano, M. C. (2018) · Clinical and Experimental Otorhinolaryngology · doi:10.21053/ceo.2018.00150 · Cited by 18
Specific immune cell and lymphatic vessel signatures identified by image analysis in renal cancer
Schraml, P., Athelogou, M., Hermanns, T., Huss, R., & Moch, H. (2019) · Modern Pathology · doi:10.1038/s41379-019-0214-z · Cited by 19
Regulation of tumor growth by leukocyte-specific protein 1 in T cells
Kwon, R., Hong, B., Lee, K.-G., Choi, E., Sabbagh, L., Cho, C., Lee, N., & Kim, W. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001180 · Cited by 21
Sato, Y., Wada, I., Odaira, K., Hosoi, A., Kobayashi, Y., Nagaoka, K., Karasaki, T., Matsushita, H., Yagi, K., Yamashita, H., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1194 · Cited by 19
Larkin, T., Das, A., Bianchi, V., Sudhaman, S., Chung, J., Alsafwani, N. S., Negm, L., Yachnis, A. T., Blatt, J. E., Hawkins, C. E., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00153 · Cited by 19
Immunological exhaustion: How to make a disparate concept operational?
Kaminski, H., Lemoine, M., & Pradeu, T. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009892 · Cited by 20
Wang, Y., Wang, X., Gao, T., Lou, C., Wang, H., Liu, Y., & Cao, A. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c03200 · Cited by 19
Perspectives for immunotherapy in endocrine cancer
Latteyer, S., Tiedje, V., Schilling, B., & Führer, D. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0169 · Cited by 20
Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine
Clark, P. M., Ebiana, V., Gosa, L., Cloughesy, T. F., & Nathanson, D. A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.181693 · Cited by 22
The Cancer-Immune Set Point in Oesophageal Cancer
Power, R. F., Lowery, M. A., Reynolds, J. V., & Dunne, M. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00891 · Cited by 19
Fallarino, F., & Blank, C. U. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01222-w · Cited by 27
Takeoka, T., Nagase, H., Kurose, K., Ohue, Y., Yamasaki, M., Takiguchi, S., Sato, E., Isobe, M., Kanazawa, T., Matsumoto, M., et al. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000162 · Cited by 19
Zhao, Q., Bi, Y., Sun, H., & Xiao, M. (2021) · Disease Markers · doi:10.1155/2021/5526885 · Cited by 21
Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery
de Sousa, E., Lérias, J. R., López-Beltrán, A., Paraschoudi, G., Condeço, C., Kamiki, J., António, P., Figueiredo, N., Carvalho, C. T., Castillo-Martín, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.592031 · Cited by 19
Immune checkpoint inhibitors and small cell lung cancer: what’s new?
Schmid, S., & Früh, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.113 · Cited by 18
Pérez-Ruiz, E., Jiménez-Castro, J., Berciano‐Guerrero, M., Valdivia, J., Estalella-Mendoza, S., Toscano, F., Artacho, M. R. D. L. B., Garrido-Siles, M., Bautista, M. J. M., Roldán, R. V., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02315-9 · Cited by 20
‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors
Gunjur, A., Manrique-Rincón, A., Klein, O., Behren, A., Lawley, T. D., Welsh, S. J., & Adams, D. J. (2022) · The Journal of Pathology · doi:10.1002/path.5907 · Cited by 20
Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives
Heppt, M. V., Gebhardt, C., Hassel, J. C., Alter, M., Gutzmer, R., Leiter, U., & Berking, C. (2022) · Cancers · doi:10.3390/cancers14194547 · Cited by 19
Aris, M., Bravo, A., Pampena, M. B., Blanco, P. A., Carri, I., Koile, D., Yankilevich, P., Levy, E. M., Barrio, M. M., & Mordoh, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00955 · Cited by 18
Haik, L., Gonthier, A., Quivy, A., Gross-goupil, M., Veillon, R., Frison, É., Ravaud, A., Domblides, C., & Daste, A. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1978540 · Cited by 18
Saidak, Z., Morisse, M. C., Chatelain, D., Sauzay, C., Houessinon, A., Guilain, N., Soyez, M., Chauffert, B., Dakpé, S., & Galmiche, A. (2018) · Anticancer Research · doi:10.21873/anticanres.12357 · Cited by 17
PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity
van Ens, D., Mousset, C. M., Hutten, T. J. A., van der Waart, A. B., Campillo-Davó, D., van der Heijden, S., Vodegel, D., Fredrix, H., Woestenenk, R., Vidal, L. P., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0966-6 · Cited by 17
Kamenšek, U., Uršič, K., Markelc, B., Čemažar, M., Dragoš, V. Š., & Serša, G. (2021) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2021.107831 · Cited by 21
Metadata
- Authors
- Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of California, Los Angeles (US)
- Venue
- Science
- Published
- 2016-05-06
- Volume
- 352
- Issue
- 6286
- Pages
- 658-660
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2346108121
- Cited by
- 748
- References
- 36
- Citations by year
- 2026: 23 · 2025: 37 · 2024: 54 · 2023: 61 · 2022: 66 · 2021: 92 · 2020: 113 · 2019: 78 · 2018: 104 · 2017: 94 · 2016: 23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-immune interactions, tumor immune microenvironment, immune checkpoint inhibitors, precision oncology, immune profiling
- MeSH terms
- Animals, Humans, Immunotherapy, Macrophages, Neoplasms, T-Lymphocytes, Biomarkers, Tumor, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Mice, Precision Medicine, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.